Contents
2011 Recommendations .................................................................................................................. 2
2013 Recommendations .................................................................................................................. 3
2015 Recommendations .................................................................................................................. 4
2011 Recommendations

- PAHO’s ProVac Initiative should continue to support national level decision-making through the use of economic evaluations grounded in local data, when available, for the future introduction of dengue vaccines. PAHO should work in coordination with other initiatives, such as the Dengue Vaccine Initiative (DVI).
- The PAHO Secretariat should review surveillance systems to ensure that they can inform vaccination policies and allow vaccination impact monitoring.
2013 Recommendations

- TAG recognizes PAHO’s work toward the harmonization of dengue surveillance systems across countries in the Americas and recommends that all countries contribute and participate in this effort.
- PAHO should support national regulatory authorities in defining harmonized regulatory pathways for the licensure of dengue vaccines.
- TAG considers important that, once licensed, dengue vaccine is not only made available to larger countries in the Region but also to smaller countries, if they so choose.
- TAG recognizes that several institutions in countries of the Americas, beyond Canada and the United States, have made great contributions to the development of new vaccines but still represent largely untapped potential. International efforts should be undertaken to strengthen and coordinate research in vaccine development across the Americas.
2015 Recommendations

- TAG recommends that the countries swiftly implement an integrated approach to reduce dengue transmission, providing training on diagnosis and clinical case management, emphasizing vector control, and improving awareness so that people know how to protect themselves and their communities from mosquitoes as stated in the World Health Assembly Resolution (2015).

- While the burden of dengue in the Americas is significant, TAG notes there is insufficient evidence to make a recommendation on vaccine introduction at this time. TAG is committed to evaluating timely new evidence as it becomes available and countries should do the same over the coming months in their own national decision-making processes.

- In coordination with other initiatives, PAHO’s ProVac Initiative should support national level decision-making regarding dengue prevention and control, through the use of economic evaluations grounded in local data.